PARKINSON'S DISEASE NEWS
24th October 2008 - New research
tremor only PARKINSON'S DISEASE
Acta Neurologica Belgica  108 (2) :
48-52 (Leventoglu A, Baysal AI.)
Even amongst those people with only tremor there were found to be different types : those with rest tremor, mainly in the upper limbs; those with rest tremor only in a lower limb; and those with only jaw tremor. Some patients with pure Parkinsonian tremor were found to be without bradykinesia or rigidity for a long time. This means that instead of the typical (and false view) of Parkinson's Disease including tremor, rigidity and bradykinesia (slowing of movement), that there were those at one extreme with only tremor, and those at the other extreme who have no tremor at all. There is therefore clearly no characteristic set of symptoms that define Parkinson's Disease.
17th October 2008 - New review
implanted neurons DEVELOP PARKINSON'S DISEASE
This review details how new cells put in to the brain to rid Parkinson's Disease develop the signs of Parkinson's Disease themselves. The Neuropathological changes in Parkinson's disease usually progress slowly and spread according to a characteristic pattern. Recent papers have shed light on this progression of pathology by examining the fate of neurons grafted into the brains of patients with Parkinson's Disease.
Two of these studies demonstrate that new healthy neurons grafted in to the brains of people with Parkinson's Disease gradually develop the same pathology as the existing neurons. According to these studies, implanted neurons developed biochemical symptoms of Parkinson's Disease after transplantation : alpha-synuclein- and ubiquitin-positive Lewy bodies. It is inevitable that any new cells will eventually function at the same insufficient rate as the existing cells, because their biochemical environment would be identical.
15th October 2008 - New research
vitamin d deficiency in parkinson's disease
Archives of Neurology  65 (10) : 1348-1352 (Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V.) Complete abstract
Researchers compared the prevalence of vitamin D deficiency in patients with Parkinson's Disease with age-matched healthy controls and patients with Alzheimer disease. Significantly more patients with Parkinson's Disease (55% of them) had insufficient vitamin D, in comparison to 36% healthy controls, and 41% in people with Alzheimer's Disease. The researchers claim that this data supports a possible role of vitamin D insufficiency in Parkinson's Disease. They suggest that further studies are needed to determine the factors contributing to these differences and elucidate the potential role of vitamin D in the cause and clinical course of Parkinson's Disease. However, Vitamin D has no role at all in the formation of dopamine, the substance whose deficiency causes Parkinson's Disease. For more information go to the Biochemistry of Parkinson's Disease.
Also, in severe cases of Vitamin D deficiency, there is no known relationship with Parkinson's Disease as there would be if Vitamin D deficiency could cause it. The primary role of Vitamin D is in the formation and structure of bone. Sunlight is a known source of Vitamin D. So the link between Vitamin D and Parkinson's Disease may be due to those people with Parkinson's Disease who have mobility problems being exposed to less sunlight. Although sunlight and certain foods are sources of Vitamin D, they are usually insufficient sources. However, vitamin supplements usually supply 50%-100% of a person's needs.
13th October 2008 - New clinical trial
Nexalin device clinical trial
The Michael J.Fox Foundation is to carry out a clinical trial using the Nexalin Device. For more information go to The Michael J.Fox Foundation. Nexalin Therapy is a technology that uses a mild stimulation of the brain to treat a variety of mood disorders, specifically Anxiety, Depression, and Insomnia.
The waveform of Nexalin is administered by placing medical grade conductive pads produced specifically for the Nexalin device on the forehead and behind each ear, which are connected to the Nexalin device with thin cables. The patient is placed in a reclining chair for the duration of a treatment session, which typically lasts for approximately forty minutes. For more information go to Nexalin Advanced Therapy. The disorders usually treated share a similar biochemistry with Parkinson's Disease. The intended effect appears to be like a milder version of DBS (Deep Brain Stimulation) but without using surgery as DBS does. In January 2008, a number of Parkinson's Disease patients carried out their own informal study. For more information go to ParkinsonsRebels.
8th October 2008 - New research
THE EFFECT OF RASAGILINE ON PARKINSON'S
The proportion of patients with OFF-periods, which is the main purpose of its use, reduced from 66% to 49%. Time spent in the OFF period was also reduced from an average of 2 hours to 45 minutes. Quality of Life improved by 15%. Rasagiline was found to give better effects than Selegiline in every respect. Besides the side effects that it causes, Rasagiline will eventually lead to an opposite effect due to a biochemical process called "feedback inhibition". This is a means the body uses to counteract anything artifical imposed on it.
3rd October 2008 - New review
PARAQUAT AS A CAUSE OF PARKINSON'S DISEASE